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Familial exudative vitreoretinopathy (FEVR) is a hereditary eye disorder that affects both the retina and vitreous
body. Autosomal recessive FEVR was diagnosed in multiple individuals from three consanguineous families of
European descent. A candidate-locus–directed genome scan shows linkage to the region on chromosome 11q ﬂanked
by markers D11S905 and D11S1314. The maximum LOD score of 3.6 at is obtained with marker D11S987.vp 0
Haplotype analysis conﬁrms that the critical region is the 22-cM (311-Mb) interval ﬂanked by markers D11S905
and D11S1314. This region contains LRP5 but not FZD4; mutations in both of these genes cause autosomal
dominant FEVR. Sequencing of LRP5 shows, in all three families, homozygous mutations R570Q, R752G, and
E1367K. This suggests that mutations in this gene can cause autosomal recessive as well as autosomal dominant
FEVR.
Familial exudative vitreoretinopathy (FEVR [MIM
133780]) is a rare childhood hereditary eye disorder that
affects both the retina and the vitreous body (Criswick
and Schepens 1969). It is clinically similar to advanced
retinopathy of prematurity, but the affected individuals
do not have a history of premature birth and oxygen
therapy. The condition is characterized by the premature
arrest of the vascularization of the peripheral retina,
leading to incomplete vascularization of the peripheral
retina. This then results in the development of hyper-
permeable blood vessels, neovascularization, and, hence,
retinal folds, retinal exudates, and tractional retinal de-
tachment in 20% of affected individuals. The disorder
is bilateral and has a high degree of penetrance and a
variable expressivity (Shastry and Hiraoka 2000). Min-
imally affected individuals do not show any visual symp-
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toms. FEVR tends to be a slowly progressive disorder,
with retinal detachment often not occurring until after
the 1st decade of life.
FEVR is inherited in autosomal dominant (adFEVR
[MIM 133780]), X-linked (MIM 305390), and au-
tosomal recessive (arFEVR [MIM 601813]) fashions,
although the autosomal dominant form is the most com-
mon. X-linked FEVR has been mapped to Xp11.4 and
has been associated with mutations in the Norrie disease
gene (ND), although genetic heterogeneity has been sug-
gested by the failure to identify mutations in some pa-
tients (Chen et al. 1993; Fullwood et al. 1993; Shas-
try et al. 1995, 1997a, 1997b). adFEVR was initially
mapped to two loci: EVR1 on chromosome 11q13-q23
(Li et al. 1992; Muller et al. 1994; Price et al. 1996;
Shastry et al. 2000; Kondo et al. 2001) and EVR3 on
chromosome 11p13-p12 (Downey et al. 2001).
Whereas the EVR3 locus has not been associated with
mutations in any speciﬁc gene, the more common EVR1
locus has been associated with mutations in two linked
genes: the Wnt-receptor frizzled-4 gene (FZD4) and the
low-density lipoprotein receptor–related protein 5 gene
(LRP5) (Robitaille et al. 2002; Toomes et al. 2004). Both
FZD4 and LRP5 are involved in the Wnt signaling path-
way, combining to bind Wnt proteins and to form a
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Figure 1 Pedigree of families 68001, 68002, and 68003. The blackened boxes correspond to affected haplotypeswith alleles that cosegregate
with the disease and that are homozygous in affected individuals.
functional ligand-receptor complex (Pinson et al. 2000).
It is interesting that norrin, the product of ND, is also
a speciﬁc high-afﬁnity ligand for FZD4 in concert with
an LRP coreceptor, activating theWnt signaling pathway
(Xu et al. 2004). Mutations associated with Norrie dis-
ease decrease Wnt signaling to 20%–80% of control
levels.
LRP5 is a member of the low-density lipoprotein re-
ceptor (LDLR) family, with four EGF precursor spacer
domains—each comprising ﬁve YWTD repeats and one
EGF repeat that together form a b-propeller structure—
followed by three LDLR ligand-binding domain motifs,
a single transmembrane domain, and a cytoplasmic tail
(Hey et al. 1998). In addition to the interactions of LRP5
with FZD4 and Wnt, the intracellular domain of LRP5
binds Axin. This binding is facilitated by Wnt and is a
part of Wnt signaling (Mao et al. 2001). LRP5 mutants
lacking the extracellular domains bind Axin constitu-
tively, inducing lymphoid enhancer-binding factor 1
(LEF1) activation by destabilizing Axin and stabilizing
b-catenin. In animal models, LRP5 has been shown to
be essential for bone accrual, eye development, and me-
tabolism of cholesterol and glucose (Kato et al. 2002;
Fujino et al. 2003). In humans, LRP5 is expressed by
osteoblasts and affects bone mass (Gong et al. 2001),
with speciﬁc LRP5 alleles associated with osteoporosis
(Mizuguchi et al. 2004). Conversely, mutations in the
amino-terminal part of LRP5 have been associated with
a variety of conditions with increased bone density that
are diagnosed as endosteal hyperostosis, Van Buchem
disease, and osteopetrosis (Van Wesenbeeck et al. 2003).
In addition to adFEVR, mutations in LRP5 have been
associated with osteoporosis-pseudoglioma syndrome
(OPPG [MIM 259770]), characterized by abnormal ret-
inal vascularization often resulting in vitreal changes and
pseudoglioma (Gong et al. 2001). Thus, mutations in
LRP5 can result in either dominant or recessive disease
affecting bone density, retinal vascularization, or both.
It is notable that a number of individuals diagnosed with
adFEVR and shown by Toomes et al. (2004) to have
LRP5 mutations also had low bone density or a history
of fractures.
DNA samples were collected from three consanguin-
eous families of European descent (families 68001,
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Table 1
LOD Scores of Markers on Chromosome 11q
MARKERS
POSITION LOD SCORE AT v p
cM Mb 0 .01 .05 .1 .2 .3 .4
D11S905 51.95 409.38  2.2 .4 .1 .3 .2 0
D11S4191 60.09 597.75 1.1 .6 1 1.1 .8 .5 .2
D11S987 67.48 … 3.6 3.5 3.1 2.7 1.8 1 .4
D11S1314 73.64 720.49 4.7 2 .8 .3 0 0 0
D11S937 79.98 775.8 7.8 2.9 1 .4 0 0 0
D11S901 85.48 815.71  .4 .6 .8 .8 .5 .2
D11S4175 91.47 899.4  .8 .3 .5 .5 .3 .1
68002, and 68003) (ﬁg. 1) with 14 individuals, of whom
6 are affected. Informed consent was obtained from each
individual studied. This study has been approved by the
ethics review board of William Beaumont Hospital
(Royal Oak, MI) and the institutional review board of
the National Eye Institute and is consistent with the
tenets of the Declaration of Helsinki. Patients were ex-
amined using indirect ophthalmoscopy and ﬂuorescein
angiography. Visual acuity was assessed in all patients.
Clinical descriptions of these families have been pub-
lished elsewhere by Shastry and Trese (1997) (family
68001) and by de Crecchio et al. (1998) (families 68002
and 68003). In brief, the two affected sisters in family
68001 also have an affected paternal uncle (a product,
along with ﬁve unaffected siblings, of the consanguin-
eous mating of individuals 9 and 10, as shown in ﬁg.
1). A fourth affected individual in this family is an af-
fected nephew of individual 9, who is himself the prod-
uct of a consanguineous mating (ﬁg. 1) (see Shastry and
Trese [1997]). Although the affected nephew—the son
of an unaffected brother of individual 9—is not the prod-
uct of a known consanguineous mating, the family be-
longs to an isolated Amish community, and it seems
likely that his parents are distantly related. Both sisters
were diagnosed at 3 years of age, at which time they
manifested typical signs of FEVR, including large retinal
folds, peripheral traction and exudates, and an avascular
demarcation line near the equator and vitreous detach-
ments. Unaffected relatives, including the parents, were
examined and showed no funduscopic abnormalities
(ﬁg. 2) (see Shastry and Trese [1997]). Neither of the
affected sisters, both 10 years old at the time of the study,
has a history of bone fractures.
The affected brother and sister in family 68002 (family
2 in de Crecchio et al. 1998) were diagnosed with retinal
detachments at ages 6 years and 8 years, respectively,
and also showed other typical signs of FEVR. They
showed no systemic symptoms, including fractures and
traumatic injuries, by ages 12 years and 10 years, re-
spectively. No additional family members are known to
be affected, including seven maternal and seven paternal
aunts and uncles. The affected sisters in family 68003
(family 1 in de Crecchio et al. 1998) were diagnosed at
ages 5 years and 7 years and have shown typical signs
of FEVR that required multiple procedures, including
photocoagulation, cryopexy, and vitrectomy. They show
no signs of systemic disease, including fractures, at ages
29 years and 31 years. Consanguinity in this family was
disclosed after publication of the article by de Crecchio
et al. (1998). No additional family members are known
to be affected, including ﬁve paternal and four maternal
aunts and uncles. In families 68002 and 68003, unaf-
fected relatives, including both pairs of parents, under-
went full ophthalmological examinations that included
ﬂuorescein angiography and showed no abnormalities,
including no vascular tortuosity. Both the presence of
consanguinity and the normal results of examination of
the unaffected parents in each family strongly support
autosomal recessive inheritance in these families. In ad-
dition, although we are unable to address bone density
speciﬁcally, the absence of fractures in the six affected
individuals in these three families, with an age range of
10–31 years, would be highly atypical for patients with
OPPG.
For linkage analysis, DNAwas extracted directly from
blood by standard phenolchloroform protocols (Smith
et al. 1989). A candidate-oriented genomewide scan was
begun with 382 ﬂuorescently labeled microsatellite
markers (ABI Linkage Mapping Set MD-10) with the
use of only a subset of samples, to conserve the limited
amounts of DNA available from some individuals. Mul-
tiplexed PCR was performed as described elsewhere
(Jiao et al. 2000). Two-point linkage analyses were per-
formed using the FASTLINK implementation of the
MLINK program of the LINKAGE program package
(Lathrop and Lalouel 1984; Cottingham et al. 1993).
For screening, equal allele frequencies were used for all
markers. For ﬁne mapping on chromosome 11, the allele
frequencies were calculated using 15 control individuals
(30 chromosomes) of European ancestry.
Evidence of signiﬁcant linkage in the genomewide
scan was ﬁrst observed with markers D11S987 and
D11S4191, which gave maximum LOD scores of 3.3 at
and 2.43 at , respectively. For ﬁne mappingvp 0 vp 0
using markers taken from the Genethon database, ad-
ditional individuals were added to the families, estimated
allele frequencies were used, and the maximum LOD
score for D11S987 increased to 3.6 at , whereas,vp 0
for D11S4191, the LOD score decreased to 1.1 at
, with a LOD score of 1.1 at (table 1). Byvp 0 vp 0.1
use of LOD scores 2 to exclude linkage in these
families, arFEVR mapped to a 21.7-cM (311-Mb) in-
terval ﬂanked by D11S905 and D11S1314. Markers
D11S901 and D11S4175, which ﬂank FZD4, both
show obligate recombinations.
Examination of the haplotypes cosegregating with
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Figure 2 Mutation screening of LRP5 in families; sequencing traces and restriction digests of ampliﬁed exons. A, Family 68001, showing
a 2302CrG sequence change in exon 10 that eliminates an MspI site, so that affected siblings show a single 386-bp fragment and heterozygotes
also show digested 212-bp and 174-bp fragments. The maternal aunt and grandmother are carriers, having both alleles. B, Family 68002,
showing a 4147GrA sequence change in exon 19 that eliminates a SacI site, so that affected individuals show a single 269-bp fragment and
heterozygotes also show digested 182-bp and 87-bp fragments. C, Family 68003, showing a 1757GrA sequence change in exon 8 that eliminates
an AciI recognition site, so that affected individuals show a single 252-bp fragment and heterozygotes also show a 179-bp fragment (the
remaining 73-bp fragment was not seen on the gel). Mutant and control (wild-type) sequence traces are shown above the restriction-enzyme-
digestion products of exons 10, 19, and 8.
arFEVR in the three families conﬁrms and extends the
linkage results. In family 68001, a recombination event
between marker D11S905 and the arFEVR locus in in-
dividual 6 provides the centromeric boundary to the
linked region. In addition, lack of homozygosity for
markers D11S905 and D11S4191 in both affected in-
dividuals suggests that the arFEVR locus might lie distal
to D11S4191 (ﬁg. 1). In family 68002, lack of homo-
zygosity in marker D11S1314 suggests that the arFEVR
locus lies proximal to that marker. Similarly, in family
68003, lack of homozygosity in markers D11S905 and
D11S1314 suggests that arFEVR lies in the same interval
suggested by the two-point linkage analysis: the linked
region between D11S905 and D11S1314 (ﬁg. 1). This
critical interval contains LRP5, in which mutations have
recently been shown to cause adFEVR. FZD4, the other
gene on chromosome 11q implicated in adFEVR and
also part of the Wnt signaling pathway, lies between
markers D11S901 and D11S4175 and is excluded from
the linked region by an obligate recombination event in
individual 7 of family 68001 and by lack of homozy-
gosity in all families.
For mutation screening of LRP5, coding exons and
adjacent intronic sequences were ampliﬁed from ge-
nomic DNA of two affected patients and one unaffected
individual. The reference genomic sequence is available
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from NCBI (accession number NM_002335). PCR am-
pliﬁcation of 23 exons by use of primers listed in table
1 of Toomes et al. (2004) was performed in 20-ml re-
actions involving 2.5 U of Taq Gold (ABI), 10# 2 ml of
Buffer Gold Taq, 1.9 mM of MgCl2, 0.25 mM of dNTP,
0.25 mM of primers, and 40 ng of genomic DNA. PCR
cycling consisted of an initial 10-min denaturation step
at 95C for 5 min; 32 cycles at 94C for 40 s, 55C for
30 s, and 72C for 30 s; and a ﬁnal elongation step at
72C for 5 min. PCR products were puriﬁed using either
a Qiagen PCR puriﬁcation kit or an Edge Biosystem
QuickStepTm2 PCR puriﬁcation kit. The PCR template
was sequenced using ABI Dye Terminator, version 1, in
a ﬁnal reaction of 10 ml. Products of the sequencing
reactions were puriﬁed using the Edge Biosystem Per-
forma TM DTR gel-ﬁltration system and were run on
a 3100 ABI genetic analyzer. Sequences were aligned
using the Seqman program of the DNASTAR program
package.
In family 68001, exon 10 of the LRP5 gene shows a
c2302CrG transversion resulting in an R752G muta-
tion in the third YWTD domain of the protein. The
2302CrG sequence change eliminates an MspI site, so
that ampliﬁcation using the sequencing primers and di-
gestion with MspI yields 212-bp and 174-bp fragments
in control alleles but yields a 386-bp fragment in mutant
alleles (ﬁg. 2A). This nonconservative change occurs in
an arginine residue evolutionarily conserved, from hu-
man to Drosophila, in LRP4, LRP5, and LRP6, when
sequences are aligned using the Clustal W algorithm as
implemented in the MegAlign program (DNASTAR). In
family 68002, exon 19 shows a c4147GrA transition
resulting in a E1367K change in the third LDLR ligand-
binding domain of the protein. The 4147GrA sequence
change eliminates a SacI site, so that ampliﬁcation with
the exon 19 sequencing primers, followed by digestion
with SacI, yields 182-bp and 87-bp fragments from con-
trol alleles but yields a single 269-bp fragment from the
mutant allele (ﬁg. 2B). In the protein, this change from
a negatively to a positively charged amino acid occurs
at a glutamate residue evolutionarily conserved, from
human to Drosophila, in LRP5 and LRP6 but not in
LRP4. Finally, affected individuals in family 68003 show
a c1757GrA transition in exon 8, resulting in a R570Q
substitution in the second YWTD domain of the protein.
This is the same residue which, when mutated to tryp-
tophan (R570W) results in the osteoporosis-pseudog-
lioma syndrome. Although bone-density measurements
are not available for these affected siblings, they have
had no fractures by ages 29 years and 31 years, which
would be distinctly unusual for OPPG, and their oph-
thalmic course is consistent with FEVR rather than
OPPG, which often presents with blindness in the neo-
natal period (Beighton et al. 1985; De Paepe et al. 1993).
The 1757GrA sequence change eliminates an AciI rec-
ognition site, so that PCR ampliﬁcation with the distal
exon 8 sequencing primers followed by digestion with
AciI yields 73-bp and 179-bp fragments in control in-
dividuals but yields a single 252-bp fragment from the
mutant allele (ﬁg. 2C). In the protein, this substitution
of a polar for a charged amino acid changes an arginine
residue evolutionarily conserved, from human to Dro-
sophila, in LRP5 and LRP6 proteins but not in LRP4
proteins from human and mouse. None of these changes
were seen in 100 control individuals (200 chromosomes)
of European ethnic extraction, when these individuals
were tested using PCR ampliﬁcation followed by diges-
tion with the appropriate restriction endonuclease.
The combination of linkage and mutation analysis
provides strong evidence that mutations in LRP5 can
cause arFEVR. Thus, mutations in LRP5 can result in
a variety of clinical presentations and can affect bone
density and retinal vascularization. Mutations that trun-
cate the protein or cause a frameshift early in the pro-
tein—in either the EGF or LDLR repeat domains—have
been described in individuals with OPPG (Gong et al.
2001). Truncation or frameshift mutations more distal
in the protein have been described in patients with
adFEVR (although one family had associated osteopo-
rosis) (Toomes et al. 2004). This was true in one mu-
tation that occurred before the transmembrane domain,
although, in this mutation, 52 novel amino acids of un-
certain effect were encoded. Missense mutations in
LRP5 can also cause a variety of clinical presentations.
A set of moderate to conservative mutations (e.g.,
G171V, G171R, A214T, A214V, A242T, and T253I) in
the ﬁrst EGF spacer domain have been shown to cause
disorders of increased bone mass (Boyden et al. 2002;
Little et al. 2002; Van Wesenbeeck et al. 2003). Other
missense mutations in the EGF repeat domains or LDLR
ligand-binding domains have been found in individuals
with OPPG (Gong et al. 2001) or adFEVR (Toomes et
al. 2004). Here, we describe three additional missense
mutations in the second and third EGF repeat and in
the third LDLR ligand-binding domain that are asso-
ciated with arFEVR. Although one would suspect that
these mutations cause milder decreases in function of the
LRP5 protein than the functional decrease associated
with adFEVR, the proof of this must await functional
studies of the mutant proteins. There also remains the
possibility that the effects of mutations in LRP5 might
vary with the genetic background, especially with regard
to other genes in the Wnt signaling pathway. Finally, it
seems likely that just as adFEVR can be caused by mu-
tations in more than one member of the Wnt signaling
pathway, arFEVR might show similar locus heteroge-
neity, which this study does not address.
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